Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use

Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer

(2019) Yan Xing et al.   JOURNAL OF NUCLEAR MEDICINE

Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.

(2019) Ila J Datar et al.   CLINICAL CANCER RESEARCH

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

(2019) Miren Zuazo et al.   EMBO Molecular Medicine

LAG-3 antagonists by cancer treatment: a patent review

(2019) Martin Perez-Santos et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy

(2019) Xiaojie Yu et al.   mAbs

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent

(2019) Broos et al.   Cancers

Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 Knock-In Mice

(2019) Elena Burova et al.   MOLECULAR CANCER THERAPEUTICS

Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody

(2018) Dan Li et al.   MOLECULAR PHARMACEUTICS

Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20

(2018) Ahmet Krasniqi et al.   New Biotechnology

Anti–CTLA-4 therapy requires an Fc domain for efficacy

(2018) Jessica R. Ingram et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy

(2018) Katrijn Broos et al.   Theranostics

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression

(2018) Robin Maximilian Awad et al.   Frontiers in Immunology

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

(2018) Jun Wang et al.   CELL

Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect

(2018) Yang Du et al.   EUROPEAN RADIOLOGY

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

(2018) Frederike Bensch et al.   NATURE MEDICINE

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

(2018) A. N. Niemeijer et al.   Nature Communications

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer

(2017) Reinhard Büttner et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

(2017) Katrijn Broos et al.   Oncotarget

Lymphocyte-activation gene-3, an important immune checkpoint in cancer

(2016) Yayi He et al.   CANCER SCIENCE

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

(2015) M. Keyaerts et al.   JOURNAL OF NUCLEAR MEDICINE

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

(2015) T. Kouo et al.   Cancer Immunology Research

LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

(2014) F. Xu et al.   CANCER RESEARCH

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies

(2013) M Lemaire et al.   LEUKEMIA

Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions

(2012) Alexis Broisat et al.   CIRCULATION RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer

(2011) Ilse Vaneycken et al.   FASEB JOURNAL